Table 2 Estimated overall and CD4-stratified* cryptococcal antigen (CrAg) prevalence by laboratory-based serum CrAg EIA and clinic-based CrAg LFA testing (N = 1,296).
#Positive | #Tested | Estimated Prevalence (95% CI) | |
|---|---|---|---|
Laboratory-based serum CrAg EIA | |||
All participants | 15 | 1,296 | 1.2% (0.6–1.9%) |
CD4 ≥200 cells/mm3 | 1 | 873 | 0.1% (0.0–0.6%) |
CD4 <200 cells/mm3 | 14 | 384 | 3.6% (2.0–6.0%) |
CD4 <100 cells/mm3 | 10 | 176 | 5.7% (2.8–10.2%) |
Clinic-based venous whole blood CrAg LFA | |||
All participants | 28 | 1,163 | 2.4% (1.6–3.5%) |
CD4 ≥200 cells/mm3 | 12 | 790 | 1.5% (0.8–2.6%) |
CD4 <200 cells/mm3 | 15 | 336 | 4.5% (2.5–7.3%) |
CD4 <100 cells/mm3 | 11 | 156 | 7.1% (3.6–12.3%) |
Clinic-based fingerprick capillary blood CrAg LFA | |||
All participants | 43 | 1,164 | 3.7% (2.7–4.9%) |
CD4 ≥200 cells/mm3 | 27 | 792 | 3.4% (2.3–4.9%) |
CD4 <200 cells/mm3 | 15 | 335 | 4.5% (2.5–7.3%) |
CD4 <100 cells/mm3 | 9 | 156 | 5.8% (2.7–10.7%) |
Clinic-based urine CrAg LFA | |||
All participants | 123 | 1,151 | 10.7% (9.0–12.6%) |
CD4 ≥200 cells/mm3 | 64 | 783 | 8.2% (6.4–10.3%) |
CD4 <200 cells/mm3 | 53 | 331 | 16.0% (12.2–20.4%) |
CD4 <100 cells/mm3 | 33 | 153 | 21.6% (15.3–28.9%) |
